HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Science Board Meeting Could Launch US Toward Lawful Hemp Use, Or Extend Market Limbo

Executive Summary

Questions FDA is asking advisors and the public could generate answers propelling it toward determining whether hemp use in supplements should be lawful with a waiver of its prohibition against using ingredients studied or approved as a drug; or, the answers could stop the FDA in its feet.

You may also be interested in...



Cannabinoids Are Test Case For US FDA Advisors’ ‘Predicted Pharmacological Activity’ Discussion

Busy agenda of disparate topics in one-day meeting likely valuable for informing FDA on safety of hemp ingredients but not for moving toward a regulatory pathway for the ingredients' lawful use in supplements and food.

Plantwise Launches Supplement Line Focusing On 'Specialized Retailers'

Plantwise launched its CBD supplements in independent pharmacies in May with consultation consumers might not receive at larger chains.

Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use

Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel